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Systems biology approaches that combine experimental data and theoretical modelling 
to understand cellular signalling network dynamics offer a useful platform to investigate the 
mechanisms of resistance to drug interventions and to identify combination drug treatments. 
Extending our work on modelling the PI3K/PTEN/AKT signalling network (SN), we analyze 
the sensitivity of the SN output signal, phospho-AKT, to inhibition of HER2 receptor. We 
model typical aberrations in this SN identified in cancer development and drug resistance: 
loss of PTEN activity, PI3K and AKT mutations, HER2 overexpression, and overproduction 
of GSK3  and CK2 kinases controlling PTEN phosphorylation. We show that HER2 
inhibition by the monoclonal antibody pertuzumab increases SN sensitivity, both to external 
signals and to changes in kinetic parameters of the proteins and their expression levels 
induced by mutations in the SN. This increase in sensitivity arises from the transition of SN 
functioning from saturation to non-saturation mode in response to HER2 inhibition. PTEN 
loss or PI3CA mutation causes resistance to anti-HER2 inhibitor and leads to the restoration 
of saturation mode in SN functioning with a consequent decrease in SN sensitivity. We 
suggest that a drug-induced increase in SN sensitivity to internal perturbations, and 
specifically mutations, causes SN fragility. In particular, the SN is vulnerable to mutations 
that compensate for drug action and this may result in a sensitivity-to-resistance transition. 
The combination of HER2 and PI3K inhibition does not sensitize the SN to internal 
perturbations (mutations) in the PI3K/PTEN/AKT pathway: this combination treatment 
provides both synergetic inhibition and may prevent the SN from acquired mutations causing 
drug resistance. Through combination inhibition treatments, we studied the impact of 
upstream and downstream interventions to suppress resistance to the HER2 inhibitor in the 
SN with PTEN loss. Comparison of experimental results of PI3K inhibition in the PTEN 
upstream pathway with PDK1 inhibition in the PTEN downstream pathway show that 
upstream inhibition abrogates resistance to pertuzumab more effectively than downstream 
inhibition. This difference in inhibition effect arises from the compensatory mechanism of an 
activation loop induced in the downstream pathway by PTEN loss. We highlight that drug 
target identification for combination anti-cancer therapy needs to account for the mutation 



















A systems biology approach to the study of anti-cancer drug action on cellular 
signalling networks (SNs) provides a useful strategy to explore SN output response to input 
stimuli [1-4], the influence of SN status on drug efficacy [2,5-7], SN target identification for 
drug design [2,8,9] and development of novel combination therapies [10,11]. An integrative 
analysis of -omics data revealed that drug efficacy depends on SN sensitivity, which is 
variable and depends on de novo or acquired mutations of receptors/proteins and their 
expression level [10,12].  The transition of SN response from sensitivity to resistance to drugs 
results from not only mutations of drug targets but mutations and cross-talk in downstream 
pathways: For example, mutations in downstream pathways lead to resistance in the case of 
anti-cancer drugs targeting the ErbB epidermal growth factor receptor (EGFR) family [12-
15]. 
Trastuzumab and pertuzumab, humanised monoclonal antibodies, target extracellular 
domains of ErbB2/HER2 receptor tyrosine kinase (RTK) and respectively prevent homo- and 
heterodimerization of the receptors HER2/HER2 and HER2/HER3 which are reported to be 
the most mitogenic signalling complexes in ovarian and breast cancer [13,16].  RTK inhibitors 
are an effective therapy against abnormal activation of ErbB signalling and constitutive 
activation of MAP kinase and PI3K/PTEN/AKT pathways that cause uncontrolled cellular 
growth [17]. While trastuzumab trials showed a high therapeutic response in tumors with 
HER2 amplification, pertuzumab (in a phase II trial) targets ovarian and breast cancer with 
any level of HER2 expression [18,19]. 
Despite the observed anti-cancer effect of these drugs, the overall analysis of in vitro 
experiments and clinical trials revealed the limitation of these drugs as mono-therapy, less 
than 35% of HER2+ patients respond to trastuzumab-based mono-therapy [20]. The results of 
an extended genetic study showed that aberrant receptor expression together with somatic 
activation mutations in downstream pathways may be mutually correlated, and generate the 
tumour phenotype resistant to anti-HER2 therapy [21]. 
One of the downstream pathways activated by ErbB receptors is the PI3K/PTEN/AKT 
pathway, which controls AKT activation and plays a key role in cell proliferation, 
differentiation and survival (see Fig. 1) [12]. Activation of AKT occurs in the 
PI3K/PTEN/AKT module, which forms a regulatory hub in cellular signalling [13]. This hub 
includes phosphoinositide 3-kinase (PI3K) and phosphatase PTEN, which control jointly the 

















product of PI3K, induces membrane localisation of PH domain-containing proteins, AKT and 
PDK1. PIP3 binding with AKT enables AKT activation through its phosphorylation by PDK1. 
PTEN relocates from the cytosol to the membrane and negatively regulates PIP3 pool by its 
dephosphorylation [22].   
Correct regulation of the PIP3 pool in the PI3K/PTEN/AKT module is essential for the 
fine tuning of signal transduction in the downstream pathway of AKT activation. An 
integrative genomic and proteomic analysis of breast and other cancers revealed that this 
regulation hub is vulnerable to mutation, and is observed to be a target of cancer-driving 
mutations that cause a transition from normal signal transduction to aberrant activation of 
AKT [23]. This transition blocks the action of the regulator hub, and fine tuned control is lost.  
Disruptions to this PI3K/PTEN/AKT pathway are known to lead to drug resistance. 
Loss of activity of the tumour suppressor PTEN was reported to be determined in nearly 50% 
of all breast cancers and many other cancers [24,25]. PTEN loss mainly results from PTEN 
mutations, loss of heterozygosity at the PTEN locus, and epigenetic down-regulation of PTEN 
[26]. Analysis of HER2 positive breast tumours revealed that a PTEN deficit correlates with 
resistance to trastuzumab-based therapy [27]. Oncogenic mutation of PI3K in the catalytic 
subunit p110  encoding PIK3CA gene was observed in up to 50% of breast cancers [28] and 
also conferred resistance to trastuzumab [25]. AKT mutations in the PH domain of AKT1 
isoform were identified in 8% of breast cancers, and this mutation causes PIP3-independent 
activation of AKT1 by recruiting it to the membrane [25]. 
Joint PTEN loss and PIK3CA mutation were reported to be frequently concordant in 
breast cancer [24,25,28,29]. Analysis of either PTEN status or PIK3CA mutation alone limits 
prognostic assessment for trastuzumab treatment, and that analysis of PTEN and PI3K status 
in combination is a superior biomarker of the resistance to anti-HER2 therapy [24]. As both 
mutations activate AKT, this finding suggests redundancy in mutation, the need for two 
alterations in the single module to activate AKT, or that PTEN loss and PIKC3 mutation 
contribute differently to carcinogenesis [25]. 
Mutual correlation of HER2 overexpression and either PIK3CA mutation or PTEN loss 
was found in approximately 25% of HER2+ breast cancer cases, and are major factor in anti-
HER2 therapy [27,30]. It is likely that HER2 overexpression and PIK3CA mutation or PTEN 
loss work together to enhance the activation of AKT. A combination of trastuzumab with 
PI3K inhibitor (LY294002, wortmannin) was observed to restore the inhibition effect of 

















of HER2, PIK3CA and PTEN as a biomarker to predict resistance to anti-HER2 therapy 
[25,29,31]. 
These experimental and clinical data support the role of the PI3K/PTEN/AKT pathway 
as a regulatory hub in the control of cell survival, which undergoes oncogenic mutations 
causing cancer development and resistance to anti-HER2 therapy. Here, we extend our study 
of the role of PI3K/PTEN/AKT signalling hub in resistance mechanisms to RTK inhibition in 
ovarian cancer cells [32,33]. In [32] we elucidated the key role of the tumour suppressor 
PTEN in resistance to anti-HER2 drugs by analysing the response kinetics of AKT activation 
to pertuzumab and justified this by the results of survival curve analysis for patients treated 
with trastuzumab for low and high PTEN expression level. 
In [33] we further developed the combined experimental and theoretical approach to 
study the mechanism underlying resistance to RTK inhibition resulting from aberrant 
expression of PI3K, PTEN and AKT enzymes.  We studied the dose dependence of AKT 
activation on pertuzumab for different perturbations of the PI3K/PTEN/AKT signalling 
pathway through manipulation of PI3K and PTEN activities by their inhibition. We 
introduced control parameter =PTEN/(PI3K AKT) which determines the balance of enzyme 
activities in this cycle. We showed that  correlates with pertuzumab efficacy for 13 ovarian 
cancer cell lines with different expression levels of the enzymes involve in this cycle. 
Together with measurement of the ratio of HER2/HER3 expression levels, parameter  was 
shown to be a biomarker of responsiveness of cancer cells to anti-HER2 therapy [33].  
In this paper we further explore the PI3K/PTEN/AKT signalling pathway by studying 
the sensitivity of the SN, i.e., how the output signal of the SN responds to the changes in 
external stimulus (activation signal and drug intervention) and internal properties of the SN 
such as catalytic characteristics of the enzymes and their expression levels, which may 
represent mutations. 
We separate out two subsystems of the whole SN: the receptor signalling system (RSS) 
and the signalling transduction system (STS) and study separately their signal response and 
sensitivity properties. The RSS subsystem comprises the reaction of ligand with receptor, 
receptor dimerization and mutual phosphorylation of receptors by receptor tyrosine kinase 
reactions, with RSS output being phosphorylated receptors (see Fig.1). The STS subsystem 
has RSS output as the input signal, and comprises PI3K/PTEN/AKT and RAF/MEK/ERK 
signalling pathways, and STS output signals are phosphorylated ERK and AKT (here, we 

















for ovarian cancer cells (using the PE04 cell line) with similar properties obtained for other 
cells [1,2,34], by comparing variation over different cell lines in both receptor signaling and 
signal transduction systems. We derive the relationship between sensitivities of these 
subsystems and calculate their contribution to the sensitivity of the whole SN. 
We analyse the sensitivity of the AKT output signal to HER2 inhibition using 
computational model of PI3K/PTEN/AKT signaling and modeling activation mutations 
identified in cancer development and drug resistance. Specifically we consider: loss of PTEN 
activity, PI3K, AKT mutations, HER2, AKT overexpression, and overproduction of GSK3  
and CK2 kinases controlling PTEN phosphorylation. We use sensitivity analysis to elucidate 
the mechanisms of SN sensitivity change as a result of the sensitivity-to-resistance transition 
arising from activation mutations and drug action.  
Through in silico and in vitro experiments, we also study combination inhibition of the 
SN to determine: 1) How to prevent acquired mutations arising from drug intervention and 
escape from oncogene addiction; and 2) How to restore sensitivity to RTK inhibitors by drug 
combination at activation mutations in the SN [12]. We consider these problems through the 
example of PTEN loss leading to pertuzumab resistance and assess in silico and in vitro the 
efficacy of the inhibition of drug targets in PTEN upstream and downstream pathways.  
 
2. Materials and methods 
2.1. Computational methods 
2.1.1. Kinetic model of RAF/MEK/ERK and PI3K/PTEN/AKT signalling  
 
To study the sensitivity-to-resistance transition and analyse the sensitivity properties of 
the signalling network to RTK inhibitors we used the kinetic model of RAF/MEK/ERK and 
PI3K/PTEN/AKT signalling developed in [32]. This model describes the response kinetics of 
the SN to heregulin (HRG)-induced HER3/HER2 receptor heterodimerisation and the effect 
of RTK inhibitor, pertuzumab (2C4 antibody), on ERK and AKT activation in the human 
ovarian carcinoma cell line PE04 [32]. The scheme of the signalling network that corresponds 
to the model is shown in Fig. 1. In the model we neglected HER4 heterodimerization because 
HER4 receptor expression was barely detectable in the PE04 cell line [32]. It was found that 
HER2/HER3 heterodimerization activates the most mitogenic signal and induces cellular 

















[32] considers only cytosol activation of AKT and ERK, without consideration of nuclear 
localisation of AKT, ERK, and PTEN [35]. 
The model was parameterised by experimental data on the phosphorylation kinetics of 
HER2, ERK, AKT, and PTEN in the absence and presence of pertuzumab and was validated 
based on experimental data on the different combination effects of PTEN, PI3K, and HER2 
inhibition on AKT activation [32,33]. 
Central to this analysis was the introduction of a control parameter, , of the 






,          (1) 

























v          
Here Km and kcat are Michaelis and catalytic constants of PTEN and PI3K enzymes which 
catalyze the reactions of phosphorylation of phosphatidylinositol (PIP2) and 
dephosphorylation of phosphatidylinositol-3,4,5-trisphosphate (PIP3), respectively; Kd,AKT – 
dissociation constant of PIP3 binding with AKT. PTENo, PI3Ko, and AKTo are initial 
concentrations of the enzymes.   
 
2.1.2. Sensitivity, resistance, and compensatory properties of the signalling network to RTK 
inhibitor 
 
In our study of the sensitivity-to-resistance transition in the SN we use the following 
definitions of system sensitivity, resistance and compensation.  
We define the sensitivity of the output signal, phospho-AKT (pAKT), of the whole 
HER2,3/PI3K/PTEN/AKT signalling network against RTK inhibitor, I, as: 
I
pAKTtIEKS oSN ),,,( ,         (2) 
which relates change in the response of output signal, pAKT, to changes in inhibitor 
concentration, I. SSN depends on the kinetic parameters of the metabolites, enzymes, proteins 
and receptors K= k1…kn, their initial concentrations Eo=e1…em, concentration of inhibitor I, 
and time after receptor stimulation, t. Here and below we consider the absolute value of 

















 In order to determine the relationship between sensitivity of the whole SN, SSN, and the 
sensitivities of the receptor signalling system, RSS, and the signalling transduction system, 
STS, we use phospho-HER2 signal (pHER2) as the interconnector between RSS and STS as a 
surrogate of receptor activation since phosphorylation of HER2 occurs in response to receptor 














                     




2),,,(          (4) 
is the sensitivity of the receptor signalling system characterising the response of the output 




pAKTtEKpHERS oSTS          (5) 
is the sensitivity of signalling transduction system, which is defined as the response of the 
output signal of STS, pAKT, to a change in the input signal of STS, pHER2.   
Therefore, and in accordance with (3), the sensitivity of the whole SN, SSN, depends on 
the sensitivities of both RSS, SRSS, and STS, SSTS. This consideration of SN sensitivity, SSN (3), 
relates to cases when an inhibitor targets the signal formed in the RSS (ErbB receptor system) 
and, in turn, this signal is transformed into the SN output signal through the STS (MAPK or 
PI3K/PTEN/AKT cascades). The specific properties of RSS and STS contributing to SRSS and 
SSTS independently, and thus the SSN overall, can be studied separately under this formulation. 
As we will show below, the STS can be sensitive with one kinetic parameter set, Ka, but 
be insensitive with another set, Kb, for the same range in input signal pHER2. Such a change 
in sensitivity may arise from mutations that modify the kinetic parameters K and/or their 
initial concentrations, Eo, and these may manifest, for example, in acquired resistance to drug 
intervention. Likewise, the STS can be sensitive to one range in input signal, pHER2, and 
insensitive in another range in input signal for a given parameter set K. This could represent 


















We also distinguish between sensitivities in both RSS and STS subsystems to changes to 
a specific parameter pi (i.e. one of the parameters in ki and ei) of the proteins/receptors 
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  (6) 
The relative sensitivities SRSS,i and SSTS,i (6) show respective relative responses 
pHER2/pHER2 and  pAKT/pAKT to relative change in the parameters, pi /pi. These 
relative sensitivities (6) are more suitable than absolute sensitivity ((2) - (5)) for the 
comparison of sensitivity across the range of different parameters as there is a wide range of 
values in this parameter set. In our computational calculation, the relative change applied to 
parameters for sensitivity analysis is always 0.1%. Below we analysed sensitivity values taken 
at time t=30 min after HRG stimulation.  
To analyse the sensitivity of SN to parameters pi we also introduce the integrative 






,  ,          (7) 
where N is the number of parameters (in ki and ei) of the model.  
We define acquired resistance to RTK inhibitor as the loss of sensitivity, SSN, of the 
output signal pAKT to inhibitor concentration, I (2), in the defined region of physiological 
concentration of inhibitor close to its IC50, i.e., SSN 0 in the resistance case. According to 
relation (3), resistance of SN to inhibitor I may arise from: 1) loss of sensitivity in RSS, SRSS  
0, for example owing to HER2 receptor mutations or overexpression; 2) loss of sensitivity in 
STS, SSTS 0, for example as a result of enzyme mutations in MAPK and/or PI3K/PTEN/AKT 
pathways. In our analysis (below), we determine the separate contributions of the sensitivities 
SRSS and SSTS to the sensitivity of the whole SN, SSN. 
We define the compensatory features of the SN as the capability of the system to 
attenuate the effect of external perturbation, for example drug intervention, due to system-
level regulation, for example feedback control or the changing of kinetic parameters, K, 
and/or expression levels, E0, resulting from mutations [33]. In the case of drug resistance, 
compensatory mechanisms act to decrease network sensitivity and this can be treated as 
emerging robustness with respect to drug action [10,37]. We explore this sensitivity-to-


















2.2. Experimental methods 
2.2.1. Cell culture and collection of lysates 
 
PE04 cells were routinely grown as monolayer cultures in DMEM supplemented with 
10% heat-inactivated fetal calf serum (FCS) and penicillin/streptomycin (100 IU/mL) in a 
humidified atmosphere of 5% CO2 at 37ºC. Time course experiments were set up by plating 
cells into 10 cm Petri dishes, which were then left for 48 hours. Cells were washed briefly in 
PBS before transfer to phenol red-free DMEM containing 5% double charcoal-stripped serum 
supplemented with penicillin/streptomycin (100 IU/mL) and glutamine (0.3 mg/mL) for a 
further 48 h prior to treatment. Cells were treated with UCN-01 (protein kinase inhibitor; 
Calbiochem #539644; final concentration of 1 μM), LY294002 (PI3 kinase inhibitor; 
Calbiochem #440204; final concentration 20 μM), pertuzumab (HER2 inhibitor; final 
concentration 100 nM) and stimulation by heregulin (R&D Systems; 396-HB-CF) was at final 
concentration of 1 nM. Cells were treated for 15 minutes with the aforementioned drugs as 
appropriate immediately followed by the addition of heregulin-β (1 nM). The concentrations 
of drugs used in the experiments corresponded to the dose causing 50% inhibition of cell 
growth. Samples were collected at 60 minutes, washed in PBS, and immediately lysed in ice-
cold isotonic lysis buffer [50 mM Tris-HCl (pH 7.5), 5 mM EGTA (pH 8.5), 150 mM NaCl, 
1% Triton X-100] supplemented with aprotinin (10 µg/mL) and a protease inhibitor cocktail 
(Roche, 11836153001). Lysates were centrifuged for 6 min at 13,000 x g and protein 
concentrations of supernatants subsequently determined using the BCA assay (Sigma, BCA-
1).  
 
2.2.2. Western Blotting  
 
Protein lysates were electrophoretically resolved on either 10% or 12% SDS-PAGE and 
transferred overnight onto Immobilon-P membranes (Millipore, Bedford, MA). After transfer, 
membranes were blocked with 1% blocking agent (Roche, #1520709) in TBS before probing 
overnight at 4˚C with the appropriate primary antibody made up in 0.5% blocking agent. 
Primary antibodies used for western blotting were as follows: anti-phospho-AKT (Ser473) 
(Cell Signaling Technology, #9271) at 1:1000; anti-PTEN (Cell Signaling Technology, #9552) 
at 1:1000. Secondary antibody detection was performed with LiCor 1:10,000 IRdye680 (for 
the normalizer) and 1:10,000 of IRdye800 (for the target) for 45 minutes at room temperature 
in dark after which cells were washed in PBS, dried and then read on a Li-Cor Odyssey 


















2.2.3. In cell Western Blotting 
 
PE04 cells were plated out in black 96-well round bottom trays and left for 24 hours 
after which they were washed in PBS and transferred to 5% double charcoal-stripped serum-
containing media as described above.  Following drug treatment, media was aspirated and 
cells were fixed in 100 µL of 4% formaldehyde for 15 minutes at room temperature before 
being washed three times in PBS.  Cells were permeabilized with 100 µL of ice-cold 
methanol for 10 minutes at -20°C and again washed in PBS.  Staining was performed by 
blocking for 60 minutes at room temperature (5% goat serum / 0.3% Triton X-100 in PBS) 
after which primary antibody incubations  (in 1% BSA / 0.3% Triton X-100 in PBS) were 
carried out overnight at 4°C.  Antibodies to pAKT (Cell Signalling; #9271 at 1:50) and total 
AKT (Cell Signalling; #2920 at 1:50, were optimized for InCell western incubations.  
Secondary antibody detection was carried out as described for western blot analysis with 
1:800 IRdye680 (for the normalizer) and 1:800 of IRdye800 (for the target).  Analysis was 
carried out after pAKT : tAKT normalization. 
 
3. Results  
3.1. Signal response characteristics and the sensitivity-to-resistance transition in the 
receptor signalling system 
 
To characterize the receptor signalling system, RSS, we studied the dose dependence of 
HER2 phosphorylation on two external signals, ligand (HRG) and drug (pertuzumab (2C4)), 
as well as on the concentration of HER2 receptors, which can vary for different cancer cell 
lines [18]. We also calculated the pAKT dose dependence on the same external signals to 
compare the responses of RSS and the whole SN.  
The theoretical and experimental dependencies of pHER2 on the concentration of HRG, 
pHER2(HRG), and pertuzumab, pHER2(2C4), are shown in Figs. 2A and 2B respectively. 
The calculation of the dose response curve, pHER2(HRG), (see thick solid line in Fig. 2A) 
showed a switch-like behaviour of pHER2 signal at HRG stimulation: RTK activation from 
10% to 100% occurs within a narrow range of HRG concentrations, and our experimental data 
showed saturation of pHER2 signal was achieved at 1 nM of HRG (see Fig. 2E).  The best fit 
to the dose response curve pHER2(HRG) by the Hill function (HRGn/(HRGn+Kn)), which 

















this indicates cooperativity in the ligand/receptor complex formation and HER2/HER3 
heterodimerization (see Fig. S1 in Supplement). EC50 obtained from theoretical dose 
dependence is consistent with experimental EC50=3 nM [16]. The pAKT dose response to 
HRG, pAKT(HRG), showed a switch-like behaviour similar to pHER2(HRG) (see thick 
dashed line in Fig. 2A). Maximal activation of AKT signal occurs within a narrow range of 
HRG concentration and its saturation is achieved at the concentration of HRG equal to 0.1 nM 
(see Fig. 2E). Thus both RSS and SN work in saturation mode at HRG concentration higher 
than 1 nM. 
The dose dependences of the output signal of RSS, pHER2(2C4), and the output signal 
of SN, pAKT(2C4), on pertuzumab concentration (2C4) are shown in Fig. 2B (thick solid and 
dashed lines respectively). The difference between these output signals is determined by the 
inherent dose response characteristics of the STS (discussed in section 3.2). The inhibition of 
HER2 receptor by 100 nM pertuzumab causes 90% inhibition of RTK, pHER2 and 80% 
inhibition of pAKT (see experimental points on thick lines in Fig. 2B).  
To model HER2 overexpression we increased 10-fold the concentration of HER2 
receptor. Note that the initial HER2/HER3 ratio in the model equals 1.4, which is close to a 
recent experimental measure for the PE04 cell line (1.6) [18]. HER2 overexpression causes a 
shift in the pHER2 and pAKT dose dependences for pertuzumab to higher concentrations (see 
thin lines in Fig. 2B). This effect leads to an increase of approximately 200 times for pHER2 
EC50 and pAKT IC50, and this 50% inhibition of pHER2 causes 10% inhibition of pAKT (see 
squares on thin lines in Fig. 2B). These results show that overexpression of HER2 causes 
insensitivity of the RSS and the whole SN to pertuzumab in the physiological range of 
pertuzumab concentrations (close to pertuzumab IC50=40 nM).  
To study pHER2 and pAKT responses to pertuzumab in a wide range of HER2 
expression levels, we calculated pHER2 and pAKT dose dependences on HER2 concentration 
in the presence and absence of 100 nM pertuzumab (see Fig. 2C). At HER2=100 nM the RSS 
and SN work in saturation mode in the absence of pertuzumab (see thick lines in Fig. 2C) and 
non-saturation mode in the presence of pertuzumab (see thin lines in Fig. 2C). With an 
increase in overexpression of HER2 by two orders of magnitude, RSS and SN return to 
function close to saturation mode in the presence of 100 nM of pertuzumab (see solid thin line 
at high concentrations of HER2 in Fig. 2C). 
Note that in our model we do not consider the ligand-independent activation of HER2 
due to HER2 homodimerization at HER2 overexpression [38], and focus on the HER2/HER3 

















increase does not change the kinetics of receptor HER2/HER3 heterodimerization and the role 
of HER2 homodimerization in AKT activation is insignificant. Our calculation relates to the 
case of a lesser level of HER2 overexpression occurring through transcriptional/translational 
mechanisms without gene amplification [38]. An extension to our model is needed to describe 
and explain the effects of ligand independent activation of HER2 [38] on trastuzumab and 
pertuzumab resistance and anomalous phosphorylation of HER2 at the action of trastuzumab 
[39] and pertuzumab [40] at HER2 amplification.  
To analyse the sensitivity of RSS to pertuzumab, we compared RSS sensitivities to the 
initial concentrations of receptors and their kinetic parameters, SRSS,i, (6) in the absence and 
presence of 100 nM pertuzumab. As seen in Fig. 3, pertuzumab causes a noticeable increase 
in pHER2 sensitivity, SRSS,I, to initial concentrations of HER2 and HRG (see white bars in Fig. 
3A) as well as to almost all kinetic parameters ki of the RSS (see white bars in Fig. 3B) 
compared to pHER2 sensitivity with no pertuzumab (black bars in Fig. 3A and B). This effect 
results from the transition of RSS kinetics from saturation to non-saturation mode due to 
HER2 inhibition by pertuzumab. In non-saturation mode the RSS becomes more sensitive to 
concentration of HER2 receptors and kinetic properties of receptors than in saturation mode.  
The transition from non-saturation to saturation mode as a result of the increase of 
HER2 concentration was indicated by a reduction in pHER2 sensitivities, SRSS,i, at pertuzumab 
action (see grey bars in Fig. 3A and B). Thus suppression of the pertuzumab inhibition effect 
from HER2 overexpression returns the pHER2 signal to the saturation region (see thin dashed 
line in Fig. 2B) and the sensitivity of the RSS to its initial low level. Note that the results of 
the sensitivity analysis of our model of the signalling in PE04 cells showed the dominant role 
of HER3 receptor in AKT signalling stimulated by HRG, where dominance is indicated by the 
size of the bar in Fig. 3A. This result is consistent with the results of sensitivity analysis of the 
model of AKT signalling in A431 [1] and ADRr cells [2] stimulated by HRG and so reflects 
the key role of HER3 receptor in HRG-induced AKT activation. The effects of pertuzumab 
and HER2 overexpression on the sensitivity SRSS,i to HER3 concentration are slight because 
the pHER2 signal remains in saturation with respect to HER3 concentration in these cases 
(see Fig. 3A). 
Our results showed the different dose responses of RSS and SN to pertuzumab (see thick 
lines pHER2(2C4) and pAKT(2C4) respectively in Fig. 2B). To analyse their mutual 
relationship, we calculated the sensitivities of RSS, STS, and the whole SN to pertuzumab, 
SRSS, SSTS, and SSN (see Fig. 2D). SRSS (4) and SSN (2) were calculated based on the pHER2 and 

















SSTS =SSN/SRSS. As shown, the sensitivity of the whole SN, SSN (solid line in Fig. 2D), overlaps 
with SRSS (dotted line in Fig. 2D) but shows more sensitivity at high pertuzumab 
concentrations. This difference between the sensitivities of SN and RSS is determined by the 
sensitivity of STS, SSTS  (dashed line in Fig. 2D), and we analyse the properties of STS in 
detail. 
 
3.2. Signal response characteristics and the sensitivity-to-resistance transition in the 
signal transduction system 
 
To study the sensitivity-to-resistance transition in the signal transduction system, STS, 
we calculated the dependence of the output signal pAKT(pHER2, ) on the input signal 
pHER2 and control parameter  (1). In Fig. 4A the dependence of pAKT(pHER2, ) is shown 
for three characteristic values of : >1 corresponding to suppression mode (dotted line); =1 
– sensitive mode (solid line), and =0.5 – resistance mode (dashed line). The dependence of 
pAKT(pHER2, ) for a wide range of pHER2 and values is provided in Fig. S2 in 
Supplement. 
We used the dependence pAKT(pHER2, ) to profile pAKT signal changes in response 
to different perturbations of the STS: specifically inhibition of input signal by pertuzumab, so 
changing pHER2 values; and PTEN, PI3K, and AKT mutations, so changing . For example, 
decreasing of pHER2 from 1 to 0.1 due to RTK inhibition causes the decrease of pAKT signal 
from saturation value 1 to 0.2 at =1 (see tracking shown by arrow from initial state (1) to 
state (2) in Fig. 4A). The loss of PTEN activity effected by decreasing  from 1 to 0.5 leads 
to restoration of the saturation of pAKT signal and confers pertuzumab resistance (see arrow 
from state (2) to state (3) in Fig. 4A).  
Thus RTK inhibition transforms the functioning state of the STS from saturation to non-
saturation mode, as depicted in the transition from initial state (1) to state (2). The functioning 
of the STS in non-saturation mode differs from when in saturation mode not only through the 
decreasing of pAKT signal but also through the increase in sensitivity of the STS to the input 
signal, pHER2. To show this, we calculated the dependence of sensitivity SSTS (5) on pHER2 
concentration and  30 minutes after HRG stimulation (see Fig. 4B). We profiled the same 
trajectory (1-2-3) as shown in Fig. 4A. A decrease in pHER2 signal as a result of RTK 

















4B). The PTEN loss leading to saturation restoration, effected through decreasing results in 
reducing SSTS sensitivity to its initial low level (transition (2-3) in Fig. 4B). 
 The increase in SSTS observed at low pHER2 signals (see states (2) in Figs. 4A and B) is 
a result of the transition from saturation to non-saturation mode at the inhibition of pHER2 
signal. In addition to the increase of SSTS, we expect an increase in the sensitivities SSTS,i  (6) to 
kinetic parameters, ki, and initial protein concentrations, ei. To study this effect we calculated 
SSTS,i (6) under different perturbations of the STS that induce this transition (see Figs. 5A and 
B). As seen, pHER2 inhibition by pertuzumab increases sensitivity SSTS,i  to the kinetic 
parameters of the reactions in PI3K/PTEN/AKT cycle and AKT phosphorylation reactions 
[32] (black and white bars in Fig. 5A and B, respectively). The increase in sensitivities SSTS,i 
(6) to ki and ei  occurs when the pertuzumab concentration in its IC50 range and where 
sensitivity SSTS to pHER2 signal increases.  
A reverse in sensitivities SSTS,i (6) was observed when effecting the sensitivity-to-
resistance transition in the PI3K/PTEN/AKT pathway at the loss of PTEN activity through 
PTEN inhibition by bpV(pic) [41] (see grey bars in Figs 5A and B), where sensitivities are 
significantly reduced compared with their increased levels at pertuzumab action alone (white 
bars). Note, the same reverse in sensitivities of STS parameters may be obtained by changing 
PI3K and AKT activities, corresponding to PIK3CA mutations and AKT overexpression 
respectively (see Fig. S3 in Supplement). Thus the sensitivity-to-resistance transition in the 
PI3K/PTEN/AKT pathway occurs with the restoration of both saturation level of pAKT signal 
and low values of sensitivities SSTS,i to kinetic parameters and initial levels of enzyme 
expression. 
The mechanism underlying the decrease in SSTS,i at low  (resistance mode) is 
determined by the saturation of PIP3 production as result of the imbalance of the enzyme 
activities in the PI3K/PTEN/AKT cycle: this imbalance leads to the restoration of saturation  
in the reaction of PIP3 binding with AKT (see next section for further analysis). Note that in 
normal functioning of the SN the concentration of PIP3 is not in saturation and the PIP2/PIP3 
balance, as controlled by the PI3K/PTEN/AKT cycle, provides the STS with a regulation 
mechanism [33].  
To study the correlation between overall sensitivity changes in the STS and different 
perturbations to PI3K/PTEN/AKT cycle we calculated integrated sensitivity S (7) and 
compared it with observed experimental levels of pAKT inhibition by different inhibitors and 

















pertuzumab+LY294002) (see Fig. 5E). pAKT inhibition is attended by an increase in 
sensitivity in the presence of either pertuzumab (bars 2) or LY294002 (bars 4) or 
pertuzumab+LY294002 (bars 5) with respect to the control (bars 1). Resistance to pAKT 
inhibition occurring in conjunction with a decreasing in S is shown in the resistance effect of 
bpV(pic) when combined with pertuzumab (bars 3). These theoretical and experimental 
results show that the sensitivity of the STS to RTK inhibition, kinetic parameters and 
expression levels of proteins is under the control of the PTEN/PI3K/AKT cycle.  We thus 
propose that the sensitivity of the STS, and so the SN as a whole, to RTK inhibition can be 
controlled by manipulation of the activity of the PTEN/PI3K/AKT cycle.  
 
3.3. Controlling sensitivity through the PTEN/PI3K/AKT cycle 
  
We have shown that an increase in sensitivity SSN to inhibitors is attended to by an 
increase in sensitivity SSTS,i to the kinetic parameters of the proteins and their expression 
levels. This means that sensitive SNs may be more fragile with respect to mutations that 
change protein kinetic properties (dissociation or/and catalytic constants) and protein 
abundance. In particular, an increasing sensitivity would appear to be an adverse effect of 
inhibitor action since a high sensitivity endows the SN with fragility with respect to mutations 
that compensate for inhibitor effect by restoring the initial low sensitivity and high output 
signal of the SN, and it is thus desirable to effect inhibition without changing SN sensitivity. 
As seen from the calculation of pAKT dose response and sensitivity depending on 
pHER2 signal and parameter  (see Fig. 4A and B), we can reach a state of high inhibition of 
pAKT  (2*) and low sensitivity (see trajectory (1-2*) in Figs 4A and B). This state (2*) can be 
obtained by RTK inhibition by pertuzumab (decrease of pHER2 signal) when increasing . 
One of the ways to achieve a high  value is to decrease PI3K activity through its inhibition 
(see equation (1) and [33]). In Fig. 4A and B we profiled RTK inhibition of the pHER2 signal 
followed by the transition from one dose response curve ( =1) to another ( >1) at inhibition of 
PI3K by 1 µM of LY294002. This combination of RTK and PI3K inhibition leads to the state 
(2*) with a sensitivity close to the unperturbed state (1) and high level of pAKT inhibition.  
Note that low sensitivity at low pHER2 signal is achieved due to the sigmoid form of the dose 
response curve pAKT(pHER2), which is more visible at higher  (see Fig. 4A).  
The sigmoid form of the dose response curve pAKT(pHER2) also affords a state of low 

















inhibition level of RTK can be reached by inhibition of HER2/HER3 heterodimerization by 
combination of trastuzumab and pertuzumab [40,42] or HER2 inhibititor combined with small 
molecular RTK inhibitors [17].  
 
3.4. Post-translation modification of PTEN and sensitivity-to-resistance transition due to 
CK2/GSK3 amplification 
 
In section 3.2 we analysed the sensitivity-to-resistance transition in the 
PI3K/PTEN/AKT pathway resulting from PTEN inactivation, which can arise from PTEN 
aberrant expression or deletion mutation [27]. Here we analyse another mechanism for loss of 
PTEN activity, due to post-translation regulation of PTEN [22]. It is known that PTEN is 
under the control of casein kinase 2 (CK2) and glycogen synthase kinase 3  (GSK3 ), which 
inactivate PTEN as a result of direct phosphorylation of the PTEN C-terminal domain [22].  
In the model, we took into account the PTEN/pPTEN cycle, and PTEN phosphorylation 
by CK2 and GSK3  enzymes is modelled by one phenomenological reaction (CK2/GSK3  
reaction in Fig. 1). pPTEN dephosphorylation is assumed to be catalysed by PTEN due to its 
weak protein phosphatase activity [22]. Experimental data on phosphorylation of PTEN 
during AKT activation was obtained in our experiments in PE04 cells [32] and in breast cells 
KPL-1 [43].   In the model, accumulation of pPTEN results from lowering the reaction rate of 
pPTEN dephosphorylation due to a decrease in the free PTEN level in the cytoplasm when 
signalling. We suggested that production of membrane PIP3 induced by PI3K activation 
causes PTEN relocation from the cytosol to the plasma membrane and that decreases 
dephosphorylation of pPTEN [22,44].  
In silico experiments showed that a further increase in the inactive form of PTEN 
(pPTEN) occurs at the overexpression of CK2 or GSK3  kinases (see Fig. S4A in 
Supplement). As a result, the imbalance in enzyme activities in the PI3K/PTEN/AKT cycle 
can effect the sensitivity-to-resistance transition in the SN. The pAKT dose-dependence for 
pertuzumab calculated at a 3-fold increase in activity of CK2/GSK3  reaction confirmed this 
(see dotted line in Fig. 2B). Amplification of the CK2/GSK3  reaction leads to a shift of 
pertuzumab IC50 by a factor of approximately 100 and thus insensitivity to pertuzumab at its 
physiological concentrations.  
Thus activation of the AKT signal may occur at the normal expression of PTEN, but at 

















constitutive expression of GSK3 . Experimentally, it was observed that hyperactivation of the 
PI3K/PTEN/AKT pathway was induced by overexpression of CK2 in lymphoblastic 
leukaemia cells [45] and by overexpression of GSK3  in an ovarian carcinoma cell line [46]. 
While CK2/GSK3  overexpression can effect the sensitivity-to-resistance transition, the 
inhibition of CK2/GSK3  kinases can reverse this transition and suppress resistance against 
RTK inhibitor resulting from the loss of PTEN activity. Modelling the effect of pertuzumab at 
the loss of PTEN activity and inhibition of PTEN phosphorylation showed particular 
suppression of resistance and restoration of sensitivity to pertuzumab (see Fig. 6B (lines)).   
We also observed that CK2/GSK3  overexpression brings about the same change in 
sensitivities SSTS,i as in the case of the direct loss of PTEN activity (see section 3.2). CK2/ 
GSK3  overexpression causes a reduction in those sensitivities that were increased as a result 
of pertuzumab action (see Fig. S4B in Supplement). The mechanism of this effect is identical 
to that of the direct loss of PTEN activities: CK2/GSK3  overexpression leading to PTEN 
inactivation restores saturation mode in the PI3K/PTEN/AKT cycle perturbed by pertuzumab.  
 
3.5. PTEN loss and the efficacy of the target inhibition in PTEN upstream and 
downstream pathways   
 
The identification of optimal drug targets to inhibit effectively pathway output signals in 
cancer cells is made especially challenging by observed de novo or acquired activating 
mutations in signalling pathways, and SN dynamics under mutations are further impacted on 
by complex feedback loops that regulate pathway activation [10,13,21,37,47]. We illustrate 
this problem by considering the effect of PTEN loss on inhibition efficacy of the targets in 
PTEN upstream and downstream pathways.   
With regard to the upstream pathway, we have shown that PTEN loss changes the SN 
response to inhibition of targets: specifically the pAKT output signal becomes insensitive to 
HER2 inhibition because of a perturbation to the balance of enzyme activities in the 
PI3K/PTEN/AKT cycle by the loss PTEN activity ( <1) [32, 33]. A combination of HER2 
inhibition together with inhibition of another target in the PTEN upstream module, PI3K 
enzyme, can overcome resistance to HER2 inhibitor at PTEN loss [28,33]. This effect is due 
to restoration of the enzyme activity balance in the PI3K/PTEN/AKT cycle by PI3K 


















Here we analyse the influence of PTEN loss on the PTEN downstream pathway and the 
efficacy of target inhibition in this pathway. In the model, PTEN inhibition leads to a two-fold 
increase in PIP3 concentration [33], and this can change the pAKT signal due to the positive 
loops of activation of downstream enzymes, AKT and PDK1. It is known that PIP3 lipids 
induce translocation of AKT and PDK1 enzymes to the plasma membrane from the cytozole 
and their activation when binding with PIP3 [48]. This positive loop of activation of PTEN 
downstream reactions may cause further AKT activation at PTEN loss. 
Our experiments with inhibition of PTEN by bpV(pic) showed no noticeable effect of 
PTEN inhibition on HRG-induced AKT activation in PE04 cells (see Fig. 6A and [32]). To 
analyse this result we calculated the pAKT dependence on PTEN concentration; similarly 
there was little observed effect of PTEN activity on pAKT signal at saturated HRG signal up 
to normal PTEN concentrations in the model, 40-50 nM (see solid line in Fig. 6B) and this 
accords with experimental data (see bars 1 and 5 in Fig. 6C). We conclude that this higher 
level of PIP3 does not influence the saturated level of active pAKT (AKT-PIP3 complex) 
reached at uninhibited PTEN. Thus, the concentration of AKT enzyme is a rate-determining 
factor in the activation of AKT by PIP3 in PE04 cells. Note that this effect depends on the 
relationship of synthesized PIP3 and initial AKT concentrations which can differ for different 
cell lines [48].   
Another consequence of PTEN loss, and following an increase in PIP3 level, is PIP3-
induced translocation of PDK1 enzyme to the plasma membrane from the cytosol and its 
activation by PIP3 [48]. Our experiment on PTEN inhibition did not show any pAKT increase 
as a result of PIP3-induced activation of PDK1 (see Fig. 6A), and so analysis of pAKT level 
does not reveal the relation between the level of PDK1 activation and the increased level of 
PIP3. At pAKT saturation, independent of the level of PIP3, PIP3-induced activation of PDK1 
may only cause an increase in the rate of AKT phosphorylation without affecting its level at 
saturation. The extent of PIP3-induced activation of PDK1 arising from PTEN loss can be 
tested by comparison of the inhibition effects of PDK1 at the different activities of PTEN.  
Our experiments showed that for normal PTEN activity, it is possible to inhibit by 
approximately 90% the pAKT signal in PE04 cells at saturated HRG signal. This may be 
through upstream (RTK) inhibitor (Fig. 5E, bar 2), downstream PDK1 inhibition with UCN-
01 [49] (Fig. 6C, bar 3), or the combination of RTK and UCN-01 inhibitors (Fig. 6C, bar 4). 
In contrast, in our experiments where PTEN activity is lost by bpV(pic) action, it is not 

















combination of RTK and UCN-01 inhibitors (Fig. 6C, bar 5) has any significant effect on the 
saturated pAKT signal. 
Thus our experiment showed that increasing activity of PDK1 due to the increase in the 
local concentration of active PDK1 reduces efficacy of PDK1 inhibition at PTEN loss in 
PE04 cells. Therefore, in contrast to the inhibition of PI3K in the PTEN upstream pathway, 
the inhibition of PDK1 in the PTEN downstream pathway at PTEN loss did not restore the 
inhibition effect of pertuzumab in PE04 cells, and this was due to the PIP3-induced activation 
loop in PTEN downstream pathway [48].  
 
3.6. PTEN-dependent and independent activation of AKT  
 
As discussed above, our in silico and in vitro experiments showed independence of 
pAKT signal on PTEN activity at saturated receptor signal in PE04 cells (see solid line in Fig. 
6B). By contrast, we also observed PTEN-dependent activation of AKT at non-saturated 
receptor signals at its inhibition by pertuzumab (see dashed line in Fig. 6B). The theoretical 
dependence of pAKT on PTEN concentration at HER2 inhibition showed an increase in 
pAKT signal at a decrease in PTEN concentration until pAKT saturation. Our experiments 
confirmed reciprocal dependence of pAKT level on PTEN activity at its inhibition by 
pertuzumab in PE04 cells [32]. Based on our modelling, we showed that PTEN loss causes 
amplification of non-saturated pHER2 signal up to saturated pAKT signal that leads to 
resistance to HER2 inhibition [32,33].  
A similar reciprocal PTEN-dependent activation of AKT was observed in our in vitro 
experimental data on the dependence of constitutive AKT activation on PTEN expression 
level in 13 ovarian cancer cell lines (see experimental points (squares) in Fig. 6B and cell 
lines characteristics in [32]). Likewise, a negative correlation between pAKT and PTEN 
expression was obtained in basal-like breast carcinoma (but not HER2+ carcinoma) [28] 
(experimental points (circles) in Fig. 6B) and other cancers [24]. Linking our theoretical 
results obtained at non-saturated receptor signal and experimental data on PTEN-dependent 
activation of AKT (see Fig. 6B) we suggested that constitutive AKT activation in cancer cells 
may be induced by weak non-saturated mitogenic signal and amplified to saturated pAKT 
level as a result of PTEN loss. Otherwise, variation in PTEN expression at saturated 
mitogenic receptor signals would not impact pAKT level, as shown in our results on PTEN-

















amplification of a weak non-saturated mitogenic signal may also result from activating 
mutations of other enzymes such as PI3K or AKT [33].  
In summary, we conclude that the effect of PTEN loss on AKT activation depends on 
the level of receptor signal. PTEN-independent activation of AKT is observed at saturated 
HRG signal and PTEN-dependent activation of AKT is observed at non-saturated receptor 
signals (for example, at receptor inhibition or weak receptor stimulus). Thus the consequences 
of PTEN loss only manifest at non-saturated receptor signal by amplification of a low pHER2 




Receptor signalling system functioning in response to HER2 inhibition and 
overexpression. We explored, through in vitro and in silico experiments based on the ovarian 
cancer cell line PE04, the whole signalling network response to HRG stimulation. We 
observed that the output signal, pAKT, was saturated with respect to HRG at concentrations 
greater than 0.1 nM. Likewise a pAKT saturation regime has been observed in the 
PDGF/PI3K/AKT signalling pathway in fibroblasts [34], and it was suggested that the 
saturated pAKT signal is insensitive to ligand concentration and more sustained in relation to 
receptor phosphorylation. Our results accord with this: sensitivity of the SN output signal to 
variation in input signal and receptor kinetic parameters is minimal when the SN functions in 
saturation regime. However, sensitivity increases when SN is not in this saturation regime, for 
example at HRG concentrations less than 0.01 nM. To explore this phenomenon in detail we 
considered the sensitivity of the receptor signalling system, RSS. 
As with the SN, the RSS output signal, pHER2, is saturated at HRG concentrations 
greater than 0.1 nM. HER2 inhibitor effects the transition of RSS from saturation to non-
saturation mode and changes both inhibited response and increased sensitivity to external and 
internal perturbations to the RSS. Our results of modelling HER2 overexpression confirmed 
that increasing HER2 expression is one of the main mechanisms underlying resistance to 
HER2 inhibitors in the RSS. We showed that HER2 overexpression leads to restoration of the 
saturated RTK signal and a consequent decrease in sensitivity to HER2 inhibition at its 
physiological concentrations. Our experimental data showed that pertuzumab efficacy to 

















HER2 expression with respect to HER3, i.e., ovarian cancer cell lines OAW42 and SKOV3 
[18].  
The signal responses of the SN and RSS to HRG stimulation are similar, with the two 
dose dependences having close EC50s and reaching saturation over a narrow range of ligand 
concentrations, which indicates activation of the SN in PE04 cells occurs at the same range of 
ligand concentrations as RSS activation. Specifically, we observed a switch-like response to 
HRG activation in both SN and RSS. More generally, the comparison of receptor system and 
whole network responses to receptor activation showed different behaviours. For example, 
while similar switch-like behaviours were observed in PDGF/PI3K/AKT signalling in 
fibroblasts [3,34] and some cancer cell lines [1], in other cancer cell lines the pAKT dose 
dependence on EGF concentration was observed to have log-linear behaviour with EC50s less 
by a factor of 0.01 to 0.1 than the receptor response to EGF [1]. To explain the switch-like 
behaviour, Perk et al. [34] proposed that the underlying mechanism is cooperative receptor 
dimerization.  
Notably, the response of the whole PI3K/PTEN/AKT signalling network in different 
cells shows more diversity in whole network response than receptor response to receptor 
activation [1]. This diversity is most likely a consequence of the dependence of the response 
of the signal transduction system to different expression levels of the proteins involved in STS 
of different cells. 
Sensitivity-to-resistance transitions through mutations in the signal transduction system: 
The response of the signal transduction system (STS), pAKT, to input signal, pHER2, showed 
that the form of the response depends on the PI3K/PTEN/AKT pathway control parameter, γ, 
and ranges from switch-like behaviour at low γ (hypersensitivity) to smooth sigmoid response 
at γ=1 (sensitivity) to suppression behaviour at γ>1 (see Fig. 4A). This behaviour, obtained 
for PE04 cells, differs from that obtained in PDGF/PI3K/AKT signalling in fibroblasts [34] 
where the receptor-signal response curve pAKT(pPDGF) was hyperbolic in form without any 
sigmoid features (see comparison of two response curves in Fig. S5 in Supplement). While 
this receptor-signal response curve varies among cell lines [1], we propose that it is possible 
to control the sensitivity-to-resistance transition through perturbations to the STS. To 
demonstrate this, we explored a range of PI3K/PTEN/AKT pathway perturbations. 
Loss of PTEN activity results in a shift in the STS signal response (pAKT) to HRG to 
lower HRG concentrations (dotted line, Fig. 2A), and the EC50 for pAKT dose dependence 
decreased by approximately one order of magnitude relative to EC50 for pHER2. Note that the 

















the STS leading to AKT activation by extremely low receptor signal (0.001 nM) and 
saturation at 5% activation of HER2 phosphorylation in PE04 cells. The PTEN-induced  
hypersensitivity of STS was caused by the transition from non-saturation to saturation in the 
PIP2/PIP3 cycle, which is controlled by the balance of PI3K, PTEN, and AKT enzyme 
activities [33]. To study the role of PTEN level in the regulation of PIP3 pool and AKT 
activation we carried out in vitro experiments on PTEN inactivation in PE04 cells. The 
experiments showed no noticeable effect of PTEN inhibition on AKT activation (see Fig. 6A). 
Thus, the excessive level of PIP3 induced by PTEN inhibition does not influence the saturated 
level of active AKT; concentration of AKT enzyme is a rate-determining factor in AKT 
activation by PIP3, confirming the suggestion that a low level of PIP3 is sufficient for AKT 
activation [34]. Further, the dominant role of initial concentration of AKT in output response 
of PE04 cells was shown through sensitivity analysis (see Fig. 5C) and this agrees with results 
of sensitivity analysis for A431 [1] and ADRr cells [2].  
In silico and in vitro experiments in PE04 cells showed that the consequences of 
perturbations to the PI3K/PTEN/AKT cycle depend on receptor signal level. For saturated 
HRG concentrations, PTEN loss does not affect AKT activation; for non-saturated HRG, 
PTEN loss causes AKT activation in the PTEN downstream pathway and SN resistance to 
upstream inhibition. Thus, the sensitivity-resistance transition occurs due to PTEN-dependent 
activation of AKT at HER2 inhibition. The same PTEN-dependent activation was observed in 
experimental data on 13 ovarian cancer cell lines (see Fig. 6B). We represented the effect of 
PTEN loss, together with PI3K mutation and CK2/GS3  overexpression, on the SN by the 
frames shown in Fig. 1 (frames 1, 2, and 3 respectively). As this effect depends on the level of 
receptor signal, frames 1, 2, and 3(absence of HER2 inhibitor) extend only over a small part 
of the pathway, whereas frames 1a, 2a, and 3a (presence of HER2 inhibitor) show that the 
influence of the PI3K/PTEN/AKT perturbation extends to the downstream pathway. Note, our 
mapping of the effect of PTEN loss, PI3K mutation and CK2/GSK3  overexpression are 
restricted to a small part of the downstream pathway of PI3K/PTEN/AKT signalling and does 
not include other PIP3-dependent processes [50]. This mapping summarizes our analysis of 
the mutation-induced perturbations in upstream and downstream pathways of the signalling 
network and can inform identification of optimal drug targets for single and combination anti-
cancer therapy. 
Preserving sensitivity of SN to mutations with combined drug interventions on the 

















external perturbations, e.g., HER2 inhibition, endow that SN with fragility with respect to 
mutations that abrogate the inhibition effect of drug. Such mutations may alter kinetic 
properties of key proteins and their expression levels, and may restore initial saturation with 
maximal output signal and significantly lower sensitivity to drug action (cancer robustness). 
We demonstrated SN fragility and acquired robustness with a combination of two inhibitors  
(UCN-01 and pertuzumab) possessing high efficacy that loses efficacy after SN mutation, 
here PTEN loss, which lowers SN sensitivity. It is thus attractive in the context of 
combination therapy to inhibit AKT activation without increasing SN sensitivity and to 
prevent cells from acquired mutations compensating for drug effect.  
We showed that the increase in SN sensitivity induced by HER2 inhibition can be 
prevented by the combination of HER2 inhibition and PI3K inhibition. In vitro experiments 
demonstrated the effectiveness of a combined pertuzumab and PI3K inhibitor (LY294002) in 
the prevention of pertuzumab resistance at PTEN loss in PE04 cells [33]. Moreover SN 
sensitivity induced by HER inhibition correlates with the unique capability of RTK inhibitors 
to sensitise cancer cells to cytotoxic drugs [8]. For example, the effect of the increase in 
sensitivity to the additional drug (docetaxel) was observed at the inhibition of HER receptors 
by cetuximab, trastuzumab, or pertuzumab in human ovarian cancer cell lines [51]. 
We explored the impact of upstream and downstream interventions, with PTEN loss as 
an example. We compared experimental results of inhibition of PI3K in the PTEN upstream 
pathway with PDK1 inhibition in the PTEN downstream pathway, and showed that upstream 
inhibition abrogated resistance to pertuzumab more effectively than downstream inhibition. 
This difference in inhibition performance was suggested to arise from an activation loop 
induced in the downstream pathway by PTEN loss. These results demonstrate the 
consequence of mutations, which can significantly change the effect of drugs targeting 




The response of AKT activation to HER2 inhibitor was studied theoretically and 
experimentally by manipulation of the receptors and enzymes activities involved in the 
PI3K/PTEN/AKT signalling network in the PE04 ovarian cancer cell line. This perturbation 
technique permitted us to model different changes in the signalling network typical in cancer 

















modeled sensitive and resistant modes in the signalling network, and observed the sensitivity-
to-resistance transition for different perturbations of the PI3K/PTEN/AKT pathway. Analysis 
of sustained activation of AKT by HRG in the absence of HER2 inhibition showed that most 
modules of the HER2,3/PI3K/PTEN/AKT pathway function in saturation with respect to 
HRG signal. We suggested that the saturation mode of activation kinetics endows the SN with 
robustness to fluctuation of the external signal as well as internal perturbations induced by 
mutations. 
Sensitivity analysis of AKT activation at HER2 inhibition showed that drug action 
significantly increased sensitivity of the response to external signal and perturbations of the 
internal properties of the SN. This effect results from that HER2 inhibitor causes the transition 
of signaling system from saturation to non-saturation mode. In in silico modeling of the 
mutation effects on SN sensitivity at anti-HER2 drug action showed that PTEN loss, PI3K 
mutations, and AKT and GSK3 /CK2 overexpression lower SN sensitivity since the system 
returns to saturation mode. Based on these results, we suggested that the drug-induced 
increase of SN sensitivity to internal perturbations leads to SN fragility with respect to 
mutations that compensate for drug effect through the sensitivity-to-resistance transition. 
Moreover, the increase in SN sensitivity at HER2 inhibition promotes using combined 
inhibition leading to the synergetic effect of two inhibitors. However, the efficacy of 
combined inhibitors can be suppressed by specific mutations in the SN. For example, through 
PTEN loss we demonstrated that the efficacy of AKT inhibition depends on the choice of the 
inhibitor target: either PTEN upstream or downstream pathways. Thus, drug target 
identification for combination anti-cancer therapy needs to account for the mutation effects on 
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Fig. 1. Scheme of MAPK and PI3K/PTEN/AKT signalling network. Frames mark the 
influence regions of mutations or aberrant expression of the enzymes: frame 1 marks the 
influence region of PIK3CA mutation; frame 2 - PTEN loss; and frame 3 - GSK3  
overexpression in the absence and presence (frames 1a, 2a, 3a, respectively) of HER2 
inhibitor, pertuzumab (2C4). 
 
Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. 
(A) pHER2 dose dependence for heregulin-  (HRG) concentration (solid line), pAKT dose 
dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM 
bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and 
dashed lines, respectively) at 95 nM and 1 µM of HER2 concentration (thick and thin lines, 
respectively). Dotted line – pAKT dose dependence at three-fold increase in activity of 
CK2/GSK3  reaction of PTEN phosphorylation. Points on thick lines – experimental data 
(see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the 
absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin 
solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole 
signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling 
transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot 
analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 
nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 minutes. 
 
Fig. 3. The sensitivity of the signaling receptor system, SRSS,i to (A) initial concentrations of 
HER2, HER3 receptors and HRG and (B) kinetic parameters of the HER2/HER3 receptor. 
Sensitivity values are derived from the model as calibrated using existing experimental data 
on pHER2 kinetics in the absence and presence of 100 nM pertuzumab (see Fig. 2A in [33]). 
The black and white bars correspond to SRSS,i in the absence and presence of 100 nM 
pertuzumab, and grey bars - HER2 overexpression in the presence of 100 nM pertuzumab. 
Only sensitivities higher than 0.01 are shown. 
 
Fig. 4. Input-output response and sensitivity characteristics of the signal transduction system, 
STS. (A) Dependence of pAKT output signal on pHER2 input signal of STS at different 

















(resistance mode), dotted line – >1 (suppression mode). Arrows show the pAKT changes at 
the different perturbations of STS: arrow 1-2 corresponds to HER2 inhibition by 100 nM 
pertuzumab; 2-3 –  decrease due to PTEN loss; 1-2* –  increase at PI3K inhibition by 1 µM 
LY294002 combined with 100 nM pertuzumab. Points 2 and 3 – experimental data [32, 33]. 
(B) Sensitivity of STS to input signal, pHER2 for different . Line notations are as in Fig. 4A. 
The concentrations of pHER2 and pAKT are normalized to their maximal concentrations. 
 
Fig. 5. Effects of HER2 inhibition and PTEN loss on sensitivity SSTS,i to the kinetic 
parameters of the enzymes involved in: (A) PI3K/PTEN cycle; (B) AKT phosphorylation; (C) 
sensitivity SSTS,i to initial concentrations of the enzymes and PIP2; and (D) sensitivity SSTS,i in 
the presence of PI3K inhibitor. Black bars – no pertuzumab, white bars – 100 nM pertuzumab, 
grey bars - 100 nM pertuzumab and PTEN inhibition by bpV(pic). Only sensitivities higher 
than 0.01 are shown. Comparison of the total sensitivity S (dark grey bars) with experimental 
data (see Fig. 4 in [33]) on pAKT inhibition by pertuzumab (light grey bars) for different 
inhibitor actions (E). Sensitivity S is normalised to maximal sensitivity in this series.  
 
Fig. 6. (A) Western blot analysis of the inhibition effect on pAKT of varying concentrations of 
PTEN inhibitor, bpV(pic) (5 nM, 10 nM, 25 nM, 50 nM, 100 nM) at 1 nM heregulin, HRG in 
PE04 cells. (B) Theoretical pAKT dose dependence on PTEN concentration at saturated HRG 
signal (solid line) and at HER2 inhibition by pertuzumab (dashed line). Squares – 
experimental data on the dependence of pAKT concentration on PTEN expression level in 13 
ovarian cancer lines (in relative units). Circles – experimental data on the dependence of 
pAKT concentration on PTEN expression for basal-like breast carcinoma (in relative units) 
[28]. (C)  Experimental data (mean ± S.D., n=3) on the effects of combinations of PDK1 
inhibition by 7.5 µM UCN-01, HER2 inhibition by 100 nM pertuzumab (2C4) and PTEN 





































































































































H i gh l i gh t s  
 
> We study the PI3K/PTEN/AKT signalling network and analyse network sensitivity 
> We model typical aberrations in this network identified in cancer and drug resistance 
> We find HER2 inhibition by pertuzumab increases signalling network sensitivity 
> PTEN loss or PI3CA mutation decreases network sensitivity 
> upstream inhibition abrogates pertuzumab resistance more effectively than downstream 
 
